References
- WHO. Global surveillance and monitoring system for substandard and falsified medicinal products. 2017. Available from: https://apps.who.int/iris/bitstream/handle/10665/326708/9789241513425-eng.pdf?ua=1
- Morris C. The threat from falsified medicines. 2015. Available from: http://www.unitrans-us.com/newsroom/Attachments_Uploads/2b-Enforcementactivities-Chris-Morris.pdf
- Otto-Knapp R, Conrad F, Hösch S, et al. Efficacy and safety of formoterol delivered through the novolizer®, a novel dry powder inhaler (DPI) compared with a standard DPI in patients with moderate to severe asthma. Pulm Pharmacol Ther. 2008;21(1):47–53.
- Ambrus R, Benke E, Farkas Á, et al. Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties. Eur J Pharm Sci. 2018;123:20–27.
- Wauthoz N, Hennia I, Ecenarro S, et al. Impact of capsule type on aerodynamic performance of inhalation products: a case study using a formoterol-lactose binary or ternary blend. Int J Pharm. 2018;553(1–2):47–56.
- Suzuki ÉY, Simon A, da Silva AL, et al. Effects of a novel roflumilast and formoterol fumarate dry powder inhaler formulation in experimental allergic asthma. Int J Pharm. 2020;588:119771.
- Guchardi R, Frei M, John E, et al. Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations. Int J Pharm. 2008;348(1–2):10–17.
- Rahimpour Y, Kouhsoltani M, Hamishehkar H. Alternative carriers in dry powder inhaler formulations. Drug Discov Today. 2014;19(5):618–626.
- Islam N, Gladki E. Dry powder inhalers (DPIs)-a review of device reliability and innovation. Int J Pharm. 2008;360(1–2):1–11.
- Jeswani HK, Azapagic A. Environmental impacts of healthcare and pharmaceutical products: Influence of product design and consumer behaviour. J Clean Prod. 2020;253:119860.
- Noriega-Fernandes B, Malmlöf M, Nowenwik M, et al. Dry powder inhaler formulation comparison: study of the role of particle deposition pattern and dissolution. Int J Pharm. 2021;607;121025.
- Yaqoubi S, Chan HK, Nokhodchi A, et al. A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols. Int J Pharm. 2021;602:120568.
- Ciza PH, Sacre PY, Waffo C, et al. Comparing the qualitative performances of handheld NIR and raman spectrophotometers for the detection of falsified pharmaceutical products. Talanta. 2019;202:469–478.
- Ciza PH, Sacre PY, Kanyonyo MR, et al. Application of NIR handheld transmission spectroscopy and chemometrics to assess the quality of locally produced antimalarial medicines in the democratic republic of Congo. Talanta Open. 2021;3:100025.
- Waffo Tchounga CA, Sacre PY, Ciza P, et al. Composition analysis of falsified chloroquine phosphate samples seized during the COVID-19 pandemic. J Pharm Biomed Anal. 2021;194:113761.
- Pedrosa de Oliveira D, Costa JSR, Oliveira-Nascimento L. Sustainability of blisters for medicines in tablet form. Sustain Chem Pharm. 2021;21:100423.
- European Medicines Agency. Guideline on the pharmaceutical quality of inhalation and nasal products. Amsterdam, Netherlands: European Medicines Agency; 2006.
- European Medicines Agency. Points to consider on the requirements for clinical documentation for Orally Inhaled Products (OIP). Amsterdam, Netherlands: European Medicines Agency; 2004.